What Charité Comprehensive Cancer Center does

The Charité Comprehensive Cancer Center (CCCC) is the largest certified cancer center in Germany and an operating division of Charité – Universitätsmedizin Berlin, a Corporation under Public Law. CCCC serves cancer patients across all tumor types, providing multidisciplinary diagnosis, treatment, palliative care, and access to precision oncology and immunotherapy services. Care is delivered through the outpatient clinic at the Rahel Hirsch Center (Luisenstr. 65, Berlin) and across Charité campuses including Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK). Patient acquisition is community-led, anchored by the Cancer-Hotline contact center (+49 30 450 564 222) and supported by referral networks from regional hospitals, specialist practices, and the ONCOnnect network. Secondary stakeholders include referring physicians and patient advocacy/self-help groups coordinated through a 100+ group directory in Berlin-Brandenburg.

The center's service portfolio integrates certified clinical care with translational research. The core offering is the CCCC multidisciplinary program holding DKG certification for over 20 organ cancer centers (breast, colorectal, head/neck, neuro-oncology, sarcoma, lung, gastric, esophageal, skin, urological, gynecological, pancreatic, liver, and others) plus DKG certification as a Center for Personalized Medicine in Oncology. Translational research is delivered through NCT Berlin — a four-institution cooperation under the German Cancer Research Center (DKFZ) with Charité, the Berlin Institute of Health (BIH), and the Max-Delbrück-Center for Molecular Medicine (MDC) — which channels basic-science findings into early-phase clinical trials. Operational sub-products include the Plattform für Personalisierte Krebsmedizin (PPK-C) with its Molekulare Tumorkonferenz and Präzisionsonkologische Sprechstunde, the Cancer-Hotline, self-help coordination, the multilingual InfoReihe KREBS patient education series, the OnkoTALK digital training platform, and clinical trial enrollment. Marketing channels span direct events, professional medical education, and a broad social media footprint.

Revenue is generated through clinical healthcare services reimbursed by German statutory health insurance (gesetzliche Krankenversicherung) and private insurance, with no direct patient pricing disclosed. Research and translational programs are funded via third-party grants — most notably Deutsche Krebshilfe's €13.8 million commitment through 2027 for the ONCOnnect Verbundprojekt connecting 14 Comprehensive Cancer Centers and 26 university hospitals. CCCC is a non-commercial public entity and does not pursue venture capital, private equity, or product licensing revenue.

Name

Charité Comprehensive Cancer Center

Legal name

Charité – Universitätsmedizin Berlin

Website

https://cccc.charite.de

Company type

Public

Operating status

Operating

Headcount range

11–50 employees

Short description

The Charité Comprehensive Cancer Center (CCCC) is Germany's largest DKG-certified cancer center, a division of Charité – Universitätsmedizin Berlin providing multidisciplinary oncology care, precision medicine, early-phase clinical trials, and translational research to cancer patients across all tumor types.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Care Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industry

Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)

Keywords

• Comprehensive cancer care
• Oncology treatment services
• Precision oncology
• Clinical cancer trials
• Multidisciplinary cancer medicine

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Clinical Healthcare Services: As a university medical center cancer center, services are funded through public healthcare insurance (gesetzliche Krankenversicherung) and private insurance reimbursement in Germany. Treatment covered under statutory health insurance.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

The Charité Comprehensive Cancer Center (CCCC) provides multidisciplinary cancer diagnosis, treatment, and care across 20+ DKG-certified organ cancer centers, integrating modern cancer medicine with translational research through the NCT Berlin cooperation for early clinical trials in precision oncology and immunotherapy. It operates a Cancer-Hotline patient contact center, molecular tumor conferences, a precision oncology clinic, self-help group coordination, the ONCOnnect regional networking initiative, and the InfoReihe KREBS patient education series. Services are delivered on a reimbursement basis through German statutory and private health insurance.

Product overview

The Charité Comprehensive Cancer Center (CCCC) is the largest certified cancer center in Germany, operating as a comprehensive oncology center with multiple organ-specific certified cancer centers. The portfolio includes the core CCCC providing multidisciplinary cancer treatment, the NCT Berlin (National Center for Tumor Diseases) enabling translational research and early clinical trials in precision oncology and immunotherapy, and the Plattform für Personalisierte Krebsmedizin (PPK-C) offering molecular tumor conferences and precision oncology consultations. Supporting services include the Cancer-Hotline for patient intake, self-help group coordination, the ONCOnnect networking initiative for regional collaboration, InfoReihe KREBS educational series, and access to clinical trials. The center integrates clinical care with research through close cooperation with Berlin Institute of Health and Max-Delbrück-Center.

Differentiator

Problem solved

Functional benefit

Brands

• NCT Berlin: Nationales Centrum für Tumorerkrankungen Berlin - cooperation for clinical Spitzenforschung and personalized cancer therapies
• Cancer-Hotline
• ONCOnnect
• PaWiKo (Patientenwissen kompakt)
• InfoReihe KREBS
• OnkoTALK
• ONKO:DIALOG

Products and services

• Charité Comprehensive Cancer Center (CCCC) Comprehensive multidisciplinary cancer diagnosis, treatment, and care delivered across 20+ DKG-certified organ cancer centers, connecting modern cancer medicine, innovative research, and holistic patient care for individuals with all cancer types.
• NCT Berlin (Nationales Centrum für Tumorerkrankungen) Translational research and early-phase clinical trial program for precision oncology and immunotherapy, a cooperation between Charité, BIH, and MDC under DKFZ that transfers basic research findings into clinical application.
• Plattform für Personalisierte Krebsmedizin der Charité (PPK-C) Platform for personalized cancer medicine at Charité, providing molecular tumor conferences and precision oncology consultations for tailored treatment approaches, targeted at referring physicians and medical professionals.
• Cancer-Hotline Central patient contact service providing appointment scheduling and routing cancer patients to the appropriate multidisciplinary specialists at CCCC and NCT Berlin.
• Präzisionsonkologische Sprechstunde (Precision Oncology Clinic) Specialized outpatient clinic delivering personalized treatment plans based on molecular profiling and the latest research findings for cancer patients eligible for precision oncology approaches.
• Molekulare Tumorkonferenz (Molecular Tumor Conference) Interdisciplinary molecular tumor board where specialists review molecular diagnostic findings to recommend personalized therapy options for patients with complex cancer cases.
• ONCOnnect am CCCC Network project connecting the Comprehensive Cancer Center with regional treatment partners (hospitals, specialist practices, self-help groups) to develop best-practice models for nationwide cancer care access, funded by Deutsche Krebshilfe with €13.8 million until 2027.
• Klinische Studien (Clinical Trials) Access to innovative oncological therapies through participation in clinical trials, including early-phase trials developed from basic research at NCT Berlin, serving patients, relatives, and referring medical professionals.

Quantifiable outcome

• Studies show patients in certified cancer centers have better treatment outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Nationales Centrum für Tumorerkrankungen (NCT) BerlincoreStrategic or Co-development PartnerNCT Berlin is a cooperation of three leading institutions from Berlin-Brandenburg under the umbrella of the German Cancer Research Center (DKFZ): Charité Universitätsmedizin Berlin, Berlin Institute of Health at Charité (BIH), and Max-Delbrück-Center für Molekulare Medizin (MDC). NCT Berlin enables early clinical trials transferring basic research into clinical practice.
• ONCOnnect Network (14 Comprehensive Cancer Centers)coreStrategic or Co-development PartnerONCOnnect is a Verbundprojekt connecting 14 DKG-funded Comprehensive Cancer Centers (CCC), 26 university hospitals, the National Cancer Prevention Center Heidelberg, and patient representatives. Goal is closer networking of CCCs with regional treatment partners.
• Berlin Institute of Health at Charité (BIH)coreStrategic or Co-development PartnerPartner in NCT Berlin cooperation for translational research bridging basic science to clinical application.
• Max-Delbrück-Center für Molekulare Medizin (MDC)coreStrategic or Co-development PartnerPartner in NCT Berlin cooperation bringing molecular medical research capabilities to cancer care translation.
• Nationales Krebspräventionszentrum HeidelbergminorStrategic or Co-development PartnerPart of ONCOnnect network focusing on cancer prevention alongside treatment and research.
• Deutsche Krebsgesellschaft (DKG)coreOthersDKG provides independent certification of organ cancer centers ensuring quality standards. CCCC holds DKG certification for over 20 organ cancer centers.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• MD Anderson Cancer Center: MD Anderson is the world's largest cancer center and a global benchmark for multidisciplinary oncology, NCI designation, and clinical trial volume. CCCC is Germany's equivalent at a national level, with the same dual emphasis on clinical care and translational research.
• Dana-Farber Cancer Institute: Dana-Farber is a Harvard-affiliated specialty cancer center with deep translational research and clinical trial activity. Comparable to CCCC for its research-clinical integration and precision oncology focus.
• Memorial Sloan Kettering Cancer Center: MSK is a globally leading specialty cancer hospital with deep clinical trial activity and molecular tumor board infrastructure. Comparable to CCCC in its pure oncology focus, translational research intensity, and certification-driven quality framework.

Regional players

• University Hospital Zurich (USZ): USZ is a leading Swiss university hospital with comprehensive oncology services and translational research capacity. Comparable structural model to CCCC as a public university hospital-based cancer center, but operating in a different national market.
• Karolinska University Hospital Comprehensive Cancer Center: Karolinska is a major Nordic university hospital with comprehensive cancer care and translational research. Comparable to CCCC as a public, academic, comprehensive cancer center with publicly funded reimbursement and clinical trial leadership.

Direct peers

• Fred Hutchinson Cancer Center: Fred Hutch is an NCI-designated comprehensive cancer center with strong translational science in immunotherapy and precision oncology. Comparable to CCCC's research-clinical integration model and clinical trial volume.
• University Hospital Heidelberg (NCT Heidelberg): Heidelberg is the founding site of the National Center for Tumor Diseases (NCT) and CCCC's most direct national peer — both operate as NCT sites under DKFZ, run DKG-certified organ cancer centers, and compete for precision oncology trials and complex patient referrals in Germany.
• University Hospital Tuebingen (CCC Tuebingen-Stuttgart): Another DKG-certified German Comprehensive Cancer Center with comparable organ cancer center structure, translational research, and competition for clinical trial enrollment and patient referrals in Germany.
• University Hospital LMU Munich (CCCM): LMU's Cancer Comprehensive Center Munich is one of the 14 DKG-certified CCCs in Germany and directly competes with CCCC for patients, clinical trials, and principal investigators in Bavaria and across southern Germany.
• University Hospital Carl Gustav Carus Dresden: GCCCD is another DKG-certified German Comprehensive Cancer Center operating as an NCT site, with comparable translational research and organ cancer center certification breadth, making it a direct national peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/chariteberlin
• YouTubeyoutube.com/@charite_berlin
• Facebookfacebook.com/ChariteUniversitaetsmedizinBerlin
• LinkedInlinkedin.com/company/charit%C3%A9-comprehensive-cancer-center
• Instagraminstagram.com/chariteberlin

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Charité Comprehensive Cancer Center